Protagonist Therapeutics Inc. (PTGX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Protagonist Therapeutics ...

    NASDAQ: PTGX · Real-Time Price · USD
    60.53
    0.93 (1.56%)
    At close: Sep 05, 2025, 3:59 PM
    60.73
    0.33%
    After-hours: Sep 05, 2025, 06:32 PM EDT

    Protagonist Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 434.43M 60M 26.58M 27.36M
    Cost of Revenue
    		 n/a n/a 1.03M 2.77M
    Gross Profit
    		 431.47M 60M 25.55M 24.58M
    Operating Income
    		 252.84M -93.65M -131.37M -125.84M
    Interest Income
    		 26.32M 14.9M 4.06M 443K
    Pretax Income
    		 279.41M -78.95M -127.39M -125.55M
    Net Income
    		 275.19M -78.95M -123.41M -122.63M
    Selling & General & Admin
    		 43.46M 33.49M 31.74M 27.2M
    Research & Development
    		 138.13M 120.16M 126.22M 126.01M
    Other Expenses
    		 n/a n/a -80K -149K
    Operating Expenses
    		 181.59M 153.65M 157.95M 153.2M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 181.59M 153.65M 157.95M 153.2M
    Income Tax Expense
    		 4.22M n/a -3.98M -2.92M
    Shares Outstanding (Basic)
    		 61.57M 56.76M 49.04M 46.32M
    Shares Outstanding (Diluted)
    		 65.08M 56.76M 49.04M 46.32M
    EPS (Basic)
    		 4.47 -1.39 -2.52 -2.65
    EPS (Diluted)
    		 4.23 -1.39 -2.52 -2.65
    EBITDA
    		 252.84M -90.34M -131.37M -123.07M
    EBIT
    		 252.84M -93.65M -131.37M -125.84M
    Depreciation & Amortization
    		 n/a 3.31M 1.03M 2.77M

    Add to Watchlist